Literature DB >> 1645813

GABAA and GABAB-receptor agonists evoked vagal nerve efferent transmission in the rat.

K Yamasaki1, Y Goto, N Hara, Y Hara.   

Abstract

The effect of GABA agonists on vagal efferent activity was studied in anesthetized rats. PCPGABA, a GABAB agonist (4 and 8 mg/kg, s.c.), markedly activated the neural efferent discharge of the vagus. Muscimol, a GABAA agonist (0.1 and 0.3 mg/kg, i.v.), also facilitated vagal activity. Both agonists caused significant gastric acid hyperacidity. Bicuculline (0.25 mg/kg, i.v.) or picrotoxin (0.5 mg/kg, i.v.) given 10 min prior to each agonist had no effect on the frequency of vagal nerve firing elicited by PCPGABA (4 mg/kg, s.c.) or muscimol (0.3 mg/kg, i.v.). Pretreatment with scopolamine (0.25 mg/kg, i.v.) abolished PCPGABA stimulated vagal activity and gastric acid secretion. Methscopolamine (0.25 mg/kg, i.v.) inhibited only the hyperacidity evoked by PCPGABA, but not vagal activation. These results suggest that PCPGABA and muscimol may cause gastric acid secretion through central cholinergic descending mechanisms that are resistant to GABAA and GABAB antagonists.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1645813     DOI: 10.1254/jjp.55.11

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  3 in total

1.  Thiopentone induced enhancement of somatic motor responses to noxious stimulation: influence of GABAA receptor modulation.

Authors:  D P Archer; A Ewen; J Froelich; S H Roth; N Samanani
Journal:  Can J Anaesth       Date:  1996-05       Impact factor: 5.063

2.  A Gut Feeling about GABA: Focus on GABA(B) Receptors.

Authors:  Niall P Hyland; John F Cryan
Journal:  Front Pharmacol       Date:  2010-10-04       Impact factor: 5.810

3.  GABAB Receptor Signaling in the Dorsal Motor Nucleus of the Vagus Stimulates Gastric Motility via a Cholinergic Pathway.

Authors:  Maureen T Cruz; Ghazaul Dezfuli; Erin C Murphy; Stefano Vicini; Niaz Sahibzada; Richard A Gillis
Journal:  Front Neurosci       Date:  2019-09-12       Impact factor: 4.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.